Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
戦略から経営上の方策まで、当社のインテリジェンスなら規制当局の承認および商業的成功まで最短ルートをとることが可能です。
医薬品がどこで承認されているかに関する情報、および承認を支持する根本的な臨床エビデンスを探すことは、ときに時間がかかり非常に困難です。また、開発プログラムに要した時間および規制当局による承認時期を知ることも重要な意味があります。
成功した承認薬および開発段階中～後期の医薬品開発パイプラインを基本的な臨床試験情報とシームレスに結び付け、最良の臨床試験デザインおよび標的の市場で成功している対照群に焦点を合わせる必要があります。各国チームと相談してこの情報を探すために多大な時間を要する可能性があります。
私たちのソリューションは、承認済みまたは開発中の興味ある疾患に関する承認薬および医薬品開発パイプラインの展望、ならびに承認に向けたスケジュールを迅速に確立するためのツールおよびインテリジェンスを提供します。作用機序または薬剤分類ごとに選別されているため、大きな時間短縮になります。
The single most comprehensive consumer healthcare information source covering regulatory, legislative, legal and commercial news across the over the counter medicines, vitamins and dietary supplements, and cosmetics industries.
Key benefits:
A well-respected and trusted industry source for the last 15 years, Generics Bulletin from Informa Pharma Intelligence provides in-depth news and analysis on issues that matter most to businesses across the generics, biosimilars and value-added medicines industries.
Key benefits:
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
14 Feb 2019
Gilead took a risky approach with selonsertib in NASH, pursuing a tough liver fibrosis benefit and failing, continuing a trend of disappointments outside of its antiviral franchises. Analysts don’t expect the second Phase III study in less-sick patients to succeed either.
Topic Drug review Drug approval Drug development landscape Clinical trials
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
14 Feb 2019
Competing combination therapies may soon be battling for attention as first-line therapies for advanced or metastatic renal cell carcinoma, with Merck & Co being the latest big pharma to release more data on the Keytruda/Inlyta combo in the setting.
Topic cancer
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
07 Feb 2019
The Swiss major's pharma chief tells Scrip that its gene therapy for SMA offers much more than Biogen's Spinraza for both patients and payers, noting that the company is ready with alternative payment models for the pricey treatment as soon as approvals for Zolgensma are granted.
Topic business-strategies drug-approval drug-development-landscape drug-review
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
07 Feb 2019
Novartis may be turning up the rhetoric in spinal muscular atrophy as its cutting-edge gene therapy Zolgensma approaches a market currently enjoyed solely by Biogen’s Spinraza, but Roche is upbeat about the potential of its investigational oral product, risdiplam, to weigh in.
Topic business-strategies drug-approval drug-development-landscape
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
01 Feb 2019
Roche will highlight newer drugs as cancer blockbusters feel biosimilar pressure, while Celgene will talk to investors about its pending acquisition by Bristol. Novo Nordisk has faced concerns about generic and branded competition not to mention price pressures, but its longer-term outlook is sound; Merck's Keytruda tops investors' focus; Gilead looks ahead to new CEO O'Day.
Topic Biosimilars Business strategies Drug approval Drug development landscape Drug review
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
By Jo Shorthouse 01 Feb 2019
As the EMA lowers the flags of the 28 EU nations that have flown outside its London offices for 24 years, and prepares to moves its HQ to the Netherlands, Scrip takes a look at Europe’s new pharma regulatory hub.
Topic business-strategies brexit
Tom Gallen 23 Jan 2019
Vegans and vegetarians looking to supplement their diet with calcium and iron helped boost overall sales of VMS products in the UK in 2018, according to data from Mintel. Total VMS sales reached £442m in 2018, with the market forecast to grow by 8% over the next five years.
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
By Brian Yang 23 Jan 2019
As a promising market for orphan drugs, China has seen several approvals in this space in the past six months, mostly from multinationals. But Beijing-based CANbridge believes that a smaller biotech also has a good shot at a leadership role, despite a lack of funding and reimbursement and prickly pricing issues.
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
23 Jan 2019
CEO Alex Gorsky highlighted growing public concern over US drug costs during J&J's Q4 earnings call, pressing for more transparency and value-based health care. The company's net drug prices declined more than 6% in 2018, he added.
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
16 Jan 2019
2019 could be a monumental year for the South Korean pharma industry, as several new drug assets await the green light from the US FDA.
Topic FDA Business strategies
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
16 Jan 2019
Annual payment plans for gene therapies appear closer to becoming reality now that bluebird bio detailed plans at J.P. Morgan. Novartis, Sarepta and others are also talking to payers about alternative payment models. Harvard Pilgrim's Michael Sherman applauded the effort in an interview.
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
10 Jan 2019
Scrip journalists asked industry executives, consultants and analysts what they believe the big themes, trends and events will be in 2019. Here's what they told us about advances in therapeutic technologies and areas of clinical innovation.
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
10 Jan 2019
News and notes from the 2019 J.P. Morgan Healthcare Conference. Pfizer CEO Bourla underscores need for scientific and commercial innovation, Gilead makes M&A a priority, Novartis' new R&D chief reflects on first meeting with CEO Narasimhan, Sarepta CEO Ingram clarifies regulatory path for micro-dystrophin, J.P. Morgan outlines deal and macro biopharma trends in 2019, and cell therapy panel discusses manufacturing challenges.
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
By Mike Ward 07 Jan 2019
Researchers from the MIT Laboratory for Financial Engineering, using clinical trials data provided by Informa Pharma Intelligence, have developed algorithms that provide a more timely, accurate and optimistic estimate of the risks and rewards of clinical trials.
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
By Viren Mehta 19 Dec 2018
Looking forward means playing the long game in biopharma. In a decade's time, it will all be about knowing every protein the AI way, something which will have transformed the industry, believes Viren Mehta, founding partner of Mehta Partners LLC.
Topic BioPharmaceutical
Scrip: 世界の医療用医薬品＆製薬産...
18 Feb 2019
Scrip: 世界の医療用医薬品＆製薬産...
17 Feb 2019
Scrip: 世界の医療用医薬品＆製薬産...
15 Feb 2019
Scrip: 世界の医療用医薬品＆製薬産...
15 Feb 2019
Scrip: 世界の医療用医薬品＆製薬産...
15 Feb 2019
Scrip: 世界の医療用医薬品＆製薬産...
15 Feb 2019
Scrip: 世界の医療用医薬品＆製薬産...
15 Feb 2019
Scrip: 世界の医療用医薬品＆製薬産...
14 Feb 2019
Scrip: 世界の医療用医薬品＆製薬産...
14 Feb 2019
Scrip: 世界の医療用医薬品＆製薬産...
14 Feb 2019
Scrip: 世界の医療用医薬品＆製薬産...
14 Feb 2019
Scrip: 世界の医療用医薬品＆製薬産...
14 Feb 2019
Scrip: 世界の医療用医薬品＆製薬産...
14 Feb 2019
Scrip: 世界の医療用医薬品＆製薬産...
14 Feb 2019
Scrip: 世界の医療用医薬品＆製薬産...
14 Feb 2019
製品説明＆デモお申込
専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。
＊一部のサービスでは無料トライアルをご利用になれません。
お問い合わせ先
ご質問等ございましたらお気軽にご連絡下さい。
日本（平日9時～18時）
電話：+81 (0)3 6273 4260
Email：inquiry.jp@informa.com
または下記のフォームよりご連絡下さい。
レポートストア
オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。
お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。
